ANGO Healthcare

AngioDynamics, Inc.

$11.73-0.26%

Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026

Basics

Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States
Market cap: 493.3M USD
Enterprise value: 439.2M USD
Full-time employees: 632

Overall health

Strength: lower risk than most peers: a steadier share price and less debt relative to equitylower risk: a steadier share price and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #857 of 1,157 healthcare companies (bottom 27%)

See how it ranks against its peers

Worth knowing

Stock pay outran buybacks. Stock-based pay expense $34M vs $2M spent repurchasing shares over the 3 fiscal years to FY May 2026.
Over three fiscal years AngioDynamics recorded $34M of stock-based pay expense and spent $2M repurchasing shares (repurchases can include shares withheld to cover employees' taxes). Repurchases were smaller than the stock pay, so they did little to offset new employee shares.Over three fiscal years AngioDynamics recorded $34M of stock-based pay expense and spent $2M repurchasing shares. Repurchases were smaller than the stock pay, so they did little to offset new employee shares.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, AngioDynamics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to August 2026.
AngioDynamics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

38/ 100

Oct 5 38 → Nov 4 38

Valuation

Is the price right?

29/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Share count down 50.0%

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-6.7%

SEC filings · 12 months to Aug 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield0.0%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsReported value50% base weight · Z-score -0.99Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield0.3%

SEC filings · 12 months to Aug 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield33.2%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

31/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ EPS growth
▼ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

The loss per share widened33% base weight · Z-score -1.20Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth-1.1%

SEC filings · 3 years to Aug 2026Reported value33% base weight · Z-score -0.82Sector median: 0.0584 · MAD: 0.0840

Revenue growth8.2%

SEC filings · 12 months to Aug 2026Reported value33% base weight · Z-score 0.22Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

25/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROIC
▼ ROA
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-11.2%

SEC filings · 12 months to Aug 2026Reported value33% base weight · Z-score -1.50Sector median: 0.0706 · MAD: 0.1217

Return on assets-13.6%

SEC filings · 12 months to Aug 2026Reported value33% base weight · Z-score -2.85Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-22.2%

SEC filings · 12 months to Aug 2026Reported value33% base weight · Z-score -2.68Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin55.7%

SEC filings · 12 months to Aug 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-20.1%

SEC filings · 12 months to Aug 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Beta
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.30

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.95Sector median: 0.6250 · MAD: 0.3380

Current ratio2.40×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.14Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.06×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about AngioDynamics

Is AngioDynamics getting weaker?: Its latest SEC filing (Oct 8, 2026) got stronger: share count down 50.0%. Its overall score is unchanged at 38/100 since Oct 28, 2026.
How is AngioDynamics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 29/100 against 1,393 healthcare peers. Earnings yield -6.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -6.7% vs peers 1.5% (weaker than 100% of peers).
Is AngioDynamics growing?: More slowly than most of its peers. Growth scores 31/100 against 1,393 healthcare peers. 3-year revenue growth -1.1% vs a peer median of 5.8% (weaker than 73% of peers).3-year revenue growth -1.1% vs peers 5.8% (weaker than 73% of peers).
How profitable is AngioDynamics?: Less profitable than most of its peers. Profitability scores 25/100 against 1,393 healthcare peers. Return on invested capital -22.2% vs a peer median of 4.7% (weaker than 80% of peers).Return on invested capital -22.2% vs peers 4.7% (weaker than 80% of peers).
How risky is AngioDynamics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.30 vs a peer median of 0.63 (stronger than 79% of peers).Beta 0.30 vs peers 0.63 (stronger than 79% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Aug 31, 2026 · filed Oct 8, 2026 · compared with the quarter ended May 31, 2026

Got stronger

Share count down 50.0%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	320.2M USD	325.4M USD	+1.6%
Net income (12 months)	−36.7M USD	−32.9M USD	−10.4%
Operating margin	-12.5%	-11.2%	+1.2 pts
Free cash flow (12 months)	508,000 USD	1.4M USD	+184.3%
Cash	53.9M USD	34.0M USD	−36.9%
Shares outstanding	84.1M	42.1M	−50.0%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Instruments & Supplies · 25 companies

Valuations in Medical Instruments & Supplies are near the bottom of their range since Jul 2018.

18% of months since Jul 2018 were valued lower than now.
0% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +17% vs the whole market, against a usual +86%.

Jul 2018Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY May 2022	FY May 2023	FY May 2024	FY May 2025	FY May 2026	Change
Gross margin	52.4%	51.4%	50.9%	53.9%	54.6%	▲ 0.7 pts
Operating margin	-9.0%	-15.1%	-63.3%	-13.7%	-12.5%	▲ 1.2 pts
Net margin	-8.4%	-15.5%	-60.7%	-11.6%	-11.5%	▲ 0.1 pts
Return on assets (ROA)	-4.8%	-9.8%	-58.0%	-12.1%	-13.8%	▼ 1.6 pts
Return on equity (ROE)	-6.3%	-13.9%	-89.7%	-18.6%	-21.5%	▼ 2.9 pts
Free cash flow margin	-3.6%	-1.1%	-10.1%	-5.0%	0.2%	▲ 5.1 pts
Current ratio	1.93×	1.95×	2.12×	2.21×	2.19×	▼ 1.0%
Quick ratio	1.24×	1.29×	1.46×	1.40×	1.49×	▲ 6.4%
Debt to equity	0.06×	0.13×	0.00×	—	—	—
Interest coverage	-41.38×	-18.94×	-119.23×	—	—	—

ANGO price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: a steadier share price and less debt relative to equitylower risk: a steadier share price and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #857 of 1,157 healthcare companies (bottom 27%)

See how it ranks against its peers

Worth knowing

Stock pay outran buybacks. Stock-based pay expense $34M vs $2M spent repurchasing shares over the 3 fiscal years to FY May 2026.

Over three fiscal years AngioDynamics recorded $34M of stock-based pay expense and spent $2M repurchasing shares (repurchases can include shares withheld to cover employees' taxes). Repurchases were smaller than the stock pay, so they did little to offset new employee shares.Over three fiscal years AngioDynamics recorded $34M of stock-based pay expense and spent $2M repurchasing shares. Repurchases were smaller than the stock pay, so they did little to offset new employee shares.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, AngioDynamics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to August 2026.

AngioDynamics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about AngioDynamics

Is AngioDynamics getting weaker?

Its latest SEC filing (Oct 8, 2026) got stronger: share count down 50.0%. Its overall score is unchanged at 38/100 since Oct 28, 2026.

How is AngioDynamics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 29/100 against 1,393 healthcare peers. Earnings yield -6.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -6.7% vs peers 1.5% (weaker than 100% of peers).

Is AngioDynamics growing?

More slowly than most of its peers. Growth scores 31/100 against 1,393 healthcare peers. 3-year revenue growth -1.1% vs a peer median of 5.8% (weaker than 73% of peers).3-year revenue growth -1.1% vs peers 5.8% (weaker than 73% of peers).

How profitable is AngioDynamics?

Less profitable than most of its peers. Profitability scores 25/100 against 1,393 healthcare peers. Return on invested capital -22.2% vs a peer median of 4.7% (weaker than 80% of peers).Return on invested capital -22.2% vs peers 4.7% (weaker than 80% of peers).

How risky is AngioDynamics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.30 vs a peer median of 0.63 (stronger than 79% of peers).Beta 0.30 vs peers 0.63 (stronger than 79% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

320.2M USD

325.4M USD

+1.6%

Net income (12 months)

−36.7M USD

−32.9M USD

−10.4%

Operating margin

-12.5%

-11.2%

+1.2 pts

Free cash flow (12 months)

508,000 USD

1.4M USD

+184.3%

Cash

53.9M USD

34.0M USD

−36.9%

Shares outstanding

84.1M

42.1M

−50.0%

Key ratios

FY May 2022

FY May 2023

FY May 2024

FY May 2025

FY May 2026

Change

Gross margin

52.4%

51.4%

50.9%

53.9%

54.6%

▲ 0.7 pts

Operating margin

-9.0%

-15.1%

-63.3%

-13.7%

-12.5%

▲ 1.2 pts

Net margin

-8.4%

-15.5%

-60.7%

-11.6%

-11.5%

▲ 0.1 pts

Return on assets (ROA)

-4.8%

-9.8%

-58.0%

-12.1%

-13.8%

▼ 1.6 pts

Return on equity (ROE)

-6.3%

-13.9%

-89.7%

-18.6%

-21.5%

▼ 2.9 pts

Free cash flow margin

-3.6%

-1.1%

-10.1%

-5.0%

0.2%

▲ 5.1 pts

Current ratio

1.93×

1.95×

2.12×

2.21×

2.19×

▼ 1.0%

Quick ratio

1.24×

1.29×

1.46×

1.40×

1.49×

▲ 6.4%

Debt to equity

0.06×

0.13×

0.00×

—

Interest coverage

-41.38×

-18.94×

-119.23×

—